|
Mycelx Technologies Corp on Tuesday said it has secured on a ‘promising’ paid trial for the treatment of per-fluoroalkyl and poly-fluoroalkyl compounds in the US.
Mycelx is a Georgia, US-based clean water and clean air technology company.
The contract is for the provision of Mycelx’s fully containerised, mobile PFAS remediation system, which includes Mycelx infused cartridge filtration and Performer media.
Mycelx said the system will be used to treat PFAS-contaminated leachate from a solid waste landfill. The company expects the rental to demonstrate the ability of its technology to completely remove all identified PFAS chemicals to non-detectable concentrations in a single pass.
PFAS, or per-fluoroalkyl and poly-fluoroalkyl compounds, are a collection of long-lasting man-made toxic chemicals which present a global threat to human health and the environment.
Revenue from the trial is not expected to alter management’s revenue expectations for the year.
‘The award is further proof of the strong momentum we are generating as a business in the PFAS solutions market, building on the Company’s success with its previous trial in America and installations in Australia with an important distributor. In addition, in scenarios of solid waste landfill, we continue to see a growing demand for technologies that are able to treat the co-contaminants that are present with PFAS,’ said Chief Executive Officer Connie Mixon.
‘As a group, we are firmly focused on achieving greater market share in three core areas; the Middle East, PFAS and REGEN. All of which we believe will be key growth drivers for Mycelx in 2023. We look forward to updating all our stakeholders on further corporate developments over the coming months,’ Mixon added.
Mycelx shares were trading 0.5% higher at 35.18 pence each in London on Tuesday morning.
By Holly Beveridge; Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
